Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Source: SeekingAlpha
2026-06-01 16:24:07 ET
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology June 1, 2026 8:00 AM EDT...
Read the full article on Seeking Alpha
For further details see:
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Agios Pharmaceuticals Inc.
NASDAQ: AGIO
AGIO Trading
-0.91% G/L:
$28.73 Last:
125,844 Volume:
$28.95 Open:
AGIO Latest News
June 01, 2026 05:00:00 am
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
May 29, 2026 07:00:00 am
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
May 22, 2026 10:18:00 am
Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
May 22, 2026 09:15:00 am
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
AGIO Stock Data
$1,577,971,753
55,806,318
0.06%
106
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
